Holen Sie sich die Stockscreener-App
14.43
6.84%
-1.06
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
ARS Pharmaceuticals - WBFF
Neffy provides needle-free relief to those with allergic reactions - KOIN.com
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
ARS Pharmaceuticals Leadership Takes Stage at 3 Major Investment Conferences This June - Stock Titan
ARS Pharmaceuticals: neffy - WCIV
Exploring US High Growth Tech Stocks In May 2025 - simplywall.st
Brent Saunders Sells 120,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus
Expert Dr. Chase shares insights on Neffy for summer allergy season - KOKH
FY2025 EPS Estimates for SPRY Cut by Cantor Fitzgerald - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Leerink Partnrs Has Bearish Outlook for SPRY Q2 Earnings - Defense World
William Blair Brokers Lower Earnings Estimates for SPRY - Defense World
Needle-Free Emergency Epinephrine Now Available for Pediatric Patients - Dermatology Advisor
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 10.8% – Still a Buy? - Defense World
Price T Rowe Associates Inc. MD Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Call Transcript - MSN
ARS Pharmaceuticals targets 80% commercial coverage for neffy in 2025 while expanding pediatric reach - MSN
Ars Pharmaceuticals’ Neffy Launch Boosts Market Prospects - TipRanks
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates - MSN
What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today - Yahoo Finance
Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15% - simplywall.st
ARS Pharmaceuticals (SPRY) Reports Strong Start with Neffy Launc - GuruFocus
Dimensional Fund Advisors LP Has $2.07 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals Reports Strong Q1 2025 Performance - TipRanks
SPRY Reports Q1 Revenue Surpassing Expectations, Preps for Key M - GuruFocus
ARS Pharmaceuticals (SPRY) Reports Strong Start with Neffy Launch in Q1 2025 - GuruFocus
ARS Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: ARS Pharmaceuticals Q1 2025 revenue beats forecast - Investing.com Nigeria
Transcript : ARS Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
ARS Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Estimates at $8.0M, EPS Misses at -$0.35 - GuruFocus
ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million - marketscreener.com
ARS PHARMACEUTICALS Earnings Results: $SPRY Reports Quarterly Earnings - Nasdaq
ARS Pharmaceuticals' Q1 Net Loss Widens, Revenue Tops Estimates - marketscreener.com
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray) - The Manila Times
ARS Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ARS Pharmaceuticals Reports First Quarter 2025 Financial - GlobeNewswire
ARS Pharma Q1 Earnings: First Needle-Free Epinephrine Spray Hits $7.8M Revenue, 57% Insurance Coverage - Stock Titan
ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
ARS Pharma’s epinephrine nasal spray 1mg now available in US - Yahoo
Neffy Maker Steps Up Awareness for MDs; Launches Kids’ Device - Allergic Living
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to - GlobeNewswire
ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx Website - marketscreener.com
ARS Pharmaceuticals And 2 Other Growth Leaders With Insider Ownership - simplywall.st
(SPRY) Investment Analysis - news.stocktradersdaily.com
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - The Manila Times
ARS Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Expected on Anaphylaxis Treatment Progress - Stock Titan
Mariner LLC Purchases 1,972 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ALK Abello inks neffy co-promotion deal in USA - The Pharma Letter
JPMorgan Chase & Co. Buys 13,190 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals Partners with ALK for Neffy Promotion By Investing.com - Investing.com Nigeria
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):